Search

Your search keyword '"Morris, Michele I."' showing total 463 results
Start Over Author "Morris, Michele I."
463 results on '"Morris, Michele I."'

101. Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts

Author

Camargo, Jose F., primary, Ahmed, Asim A., additional, Lindner, Martin S., additional, Morris, Michele I., additional, Anjan, Shweta, additional, Anderson, Anthony D., additional, Prado, Clara E., additional, Dalai, Sudeb C., additional, Martinez, Octavio V., additional, and Komanduri, Krishna V., additional

Published
2019
Full Text
View/download PDF

104. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre‐ and post‐direct‐acting antiviral therapy eras: 10‐Year single center experience

Author

Camargo, Jose F., primary, Anjan, Shweta, additional, Chin‐Beckford, Nafeesa, additional, Morris, Michele I., additional, Abbo, Lilian M., additional, Simkins, Jacques, additional, Ciancio, Gaetano, additional, Chen, Linda J., additional, Burke, George W., additional, Figueiro, Jose, additional, Guerra, Giselle, additional, Kupin, Warren L., additional, Mattiazzi, Adela, additional, Ortigosa‐Goggins, Mariella, additional, Ram Bhamidimarri, Kalyan, additional, and Roth, David, additional

Published
2019
Full Text
View/download PDF

108. Saddle Nose Deformity in an Immunosuppressed Patient

Author

Anjan, Shweta, primary, Morillas, Jose, additional, Simkins, Jacques, additional, Martinez, Octavio V, additional, Holung, Michelle, additional, Prado, Clara, additional, Jimenez, Antonio, additional, Lekakis, Lazaros J, additional, Komanduri, Krishna, additional, Morris, Michele I, additional, and Camargo, Jose F, additional

Published
2019
Full Text
View/download PDF

109. Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients1

Author

Vergidis, Pascalis, Ariza-Heredia, Ella J, Nellore, Anoma, Kotton, Camille N, Kaul, Daniel R, Morris, Michele I, Kelesidis, Theodoros, Shah, Harshal, Park, Seo Young, Nguyen, M Hong, and Razonable, Raymund R

Subjects
Adult, Adolescent, opportunistic infection, Clinical Sciences, Opportunistic Infections, Microbiology, Immunocompromised Host, Young Adult, Risk Factors, Odds Ratio, Humans, Rhodococcus, Child, Preschool, bacteria, hematopoietic stem cell transplant, Aged, transplant recipients, Hematopoietic Stem Cell Transplantation, solid organ transplant, Organ Transplantation, Middle Aged, infection, Anti-Bacterial Agents, Medical Microbiology, Case-Control Studies, Public Health and Health Services, Actinomycetales Infections, Immunosuppressive Agents
Abstract

We conducted a case-control study of 18 US transplant recipients with Rhodococcus infection and 36 matched controls. The predominant types of infection were pneumonia and bacteremia. Diabetes mellitus and recent opportunistic infection were independently associated with disease. Outcomes were generally favorable except for 1 relapse and 1 death.

Published
2017

114. 2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?

Author

Abbo, Lilian M, primary, Yasmin, Mohamad, additional, Marshall, Steven H, additional, Perez, Federico, additional, Corzo-Pedrosa, Mónica, additional, Camargo, Jose F, additional, Simkins, Jacques, additional, Aragon, Laura, additional, Anjan, Shweta, additional, Morris, Michele I, additional, Brozzi, Nicolas, additional, Loebe, Mathias, additional, Fulmer, Jesse, additional, Sinha, Neeraj, additional, Martinez, Octavio, additional, Perez-Cardona, Armando, additional, Colin, Andrew, additional, Cloke, Christina, additional, and Bonomo, Robert A, additional

Published
2018
Full Text
View/download PDF

115. How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers

Author

Sundermann, Alexander J, primary, Clancy, Cornelius J, additional, Pasculle, A William, additional, Liu, Guojun, additional, Cumbie, Richard B, additional, Driscoll, Eileen, additional, Ayres, Ashley, additional, Donahue, Lisa, additional, Pergam, Steven A, additional, Abbo, Lilian, additional, Andes, David R, additional, Chandrasekar, Pranatharthi, additional, Galdys, Alison L, additional, Hanson, Kimberly E, additional, Marr, Kieren A, additional, Mayer, Jeanmarie, additional, Mehta, Seema, additional, Morris, Michele I, additional, Perfect, John, additional, Revankar, Sanjay G, additional, Smith, Becky, additional, Swaminathan, Sankar, additional, Thompson, George R, additional, Varghese, Merin, additional, Vazquez, Jose, additional, Whimbey, Estella, additional, Wingard, John R, additional, and Nguyen, M Hong, additional

Published
2018
Full Text
View/download PDF

116. A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis ofClostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Author

Mullane, Kathleen M, primary, Winston, Drew J, additional, Nooka, Ajay, additional, Morris, Michele I, additional, Stiff, Patrick, additional, Dugan, Michael J, additional, Holland, Henry, additional, Gregg, Kevin, additional, Adachi, Javier A, additional, Pergam, Steven A, additional, Alexander, Barbara D, additional, Dubberke, Erik R, additional, Broyde, Natalya, additional, Gorbach, Sherwood L, additional, and Sears, Pamela S, additional

Published
2018
Full Text
View/download PDF

118. A cluster of donor-derivedCryptococcus neoformansinfection affecting lung, liver, and kidney transplant recipients: Case report and review of literature

Author

Camargo, Jose F., primary, Simkins, Jacques, additional, Schain, Denise C., additional, Gonzalez, A. Adrian, additional, Alcaide, Maria L., additional, Anjan, Shweta, additional, Guerra, Giselle, additional, Roth, David, additional, Kupin, Warren L., additional, Mattiazzi, Adela, additional, Tan, Yaohong, additional, Milikowski, Clara, additional, Morris, Michele I., additional, and Abbo, Lilian M., additional

Published
2018
Full Text
View/download PDF

119. A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases

Author

Revankar, Sanjay G., Baddley, John W., Chen, Sharon C. -A., Kauffman, Carol A., Slavin, Monica, Vazquez, Jose A., Seas, Carlos, Morris, Michele I., Nguyen, M. Hong, Shoham, Shmuel, Thompson, George R., III, Alexander, Barbara D., Simkins, Jacques, Ostrosky-Zeichner, Luis, Mullane, Kathleen, Alangaden, George, Andes, David R., Cornely, Oliver A., Wahlers, Kerstin, Lockhart, Shawn R., Pappas, Peter G., Revankar, Sanjay G., Baddley, John W., Chen, Sharon C. -A., Kauffman, Carol A., Slavin, Monica, Vazquez, Jose A., Seas, Carlos, Morris, Michele I., Nguyen, M. Hong, Shoham, Shmuel, Thompson, George R., III, Alexander, Barbara D., Simkins, Jacques, Ostrosky-Zeichner, Luis, Mullane, Kathleen, Alangaden, George, Andes, David R., Cornely, Oliver A., Wahlers, Kerstin, Lockhart, Shawn R., and Pappas, Peter G.

Abstract

Background. Phaeohyphomycosis is infection caused by dematiaceous, or darkly pigmented, fungi. The spectrum of disease is broad, and optimal therapy remains poorly defined. The Mycoses Study Group established an international case registry of patients with proven/probable phaeohyphomycosis with the goal of improving the recognition and management of these infections. Methods. Patients from 18 sites in 3 countries were enrolled from 2009-2015. Cases were categorized as local superficial, local deep (pulmonary, sinus, osteoarticular infections), and disseminated infections. End points were clinical response (partial and complete) and all-cause mortality at 30 days and end of follow-up. Results. Of 99 patients, 32 had local superficial infection, 41 had local deep infection, and 26 had disseminated infection. The most common risk factors were corticosteroids, solid organ transplantation, malignancy, and diabetes. Cultures were positive in 98% of cases. All-cause mortality was 16% at 30 days and 33% at end of follow-up, and 18 of 26 (69%) with dissemination died. Itraconazole was most commonly used for local infections, and voriconazole was used for more severe infections, often in combination with terbinafine or amphotericin B. Conclusions. Phaeohyphomycosis is an increasingly recognized infection. Culture remains the most frequently used diagnostic method. Triazoles are currently the drugs of choice, often combined with other agents. Further studies are needed to develop optimal therapies for disseminated infections.

Published
2017

120. Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study

Author

Manuel, Oriol, Husain, Shahid, Kumar, Deepali, Zayas, Carlos, Mawhorter, Steve, Levi, Marilyn E., Kalpoe, Jayant, Lisboa, Luiz, Ely, Leticia, Kaul, Daniel R., Schwartz, Brian S., Morris, Michele I., Ison, Michael G., Yen-Lieberman, Belinda, Sebastian, Anthony, Assi, Maha, Humar, Atul, Manuel, Oriol, Husain, Shahid, Kumar, Deepali, Zayas, Carlos, Mawhorter, Steve, Levi, Marilyn E., Kalpoe, Jayant, Lisboa, Luiz, Ely, Leticia, Kaul, Daniel R., Schwartz, Brian S., Morris, Michele I., Ison, Michael G., Yen-Lieberman, Belinda, Sebastian, Anthony, Assi, Maha, and Humar, Atul

Abstract

In high-risk solid-organ transplant recipients receiving antiviral prophylaxis, the measurement of specific cell-mediated immunity using the Quantiferon assay appropriately stratified the individual risk of developing subsequent cytomegalovirus disease

Published
2017

122. Impact of Cytomegalovirus (CMV) Viral Load on Probability of Spontaneous Clearance and Efficacy of Pre-Emptive Therapy Among CMV Seropositive Allogeneic Stem Cell Transplant Recipients

Author

Camargo, Jose F., primary, Shimose, Luis, additional, Bueno, Maria X., additional, Rosa, Rossana, additional, Jeyakumar, Nikeshan, additional, Morris, Michele I., additional, Abbo, Lilian M., additional, Simkins, Jacques, additional, Alencar, Maritza C., additional, Benjamin, Cara L., additional, Wieder, Eric, additional, Kimble, Erik L., additional, Jimenez, Antonio M., additional, Beitinjaneh, Amer, additional, Goodman, Mark, additional, Byrnes, John J., additional, Lekakis, Lazaros, additional, Pereira, Denise, additional, and Komanduri, Krishna V., additional

Published
2017
Full Text
View/download PDF

124. Clinical Outcomes in HIV+/HCV+ Co-infected Kidney Transplant Recipients in the Pre- and Post-direct Acting Antiviral (DAA) Therapy Eras: 10-year Single-center Experience

Author

Anjan, Shweta, primary, Camargo, Jose F, additional, Morris, Michele I, additional, Abbo, Lilian M, additional, Simkins, Jacques, additional, Guerra, Gisele, additional, Kupin, Warren, additional, Mattiazzi, Adela, additional, Chen, Linda, additional, Burke, George, additional, Figueiro, Jose, additional, Ruiz, Phillip, additional, Bhamidimarri, Kalyan, additional, and Roth, David, additional

Published
2017
Full Text
View/download PDF

126. Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases

Author

Rosa, Rossana, primary, Suarez, Jose F., additional, Lorio, Marco A., additional, Morris, Michele I., additional, Abbo, Lilian M., additional, Simkins, Jacques, additional, Guerra, Giselle, additional, Roth, David, additional, Kupin, Warren L., additional, Mattiazzi, Adela, additional, Ciancio, Gaetano, additional, Chen, Linda J., additional, Burke, George W., additional, Figueiro, Jose M., additional, Ruiz, Phillip, additional, and Camargo, Jose F., additional

Published
2016
Full Text
View/download PDF

127. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Author

La Hoz, Ricardo M. and Morris, Michele I.

Subjects
*INTESTINAL parasites, *ENTAMOEBA histolytica, *GIARDIA lamblia, *CRYPTOSPORIDIUM, *COMMUNICABLE diseases, *COMMUNITIES of practice, *ECHINOCOCCUS, *EMERGING infectious diseases
Abstract

These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of intestinal parasites in the pre‐ and post‐transplant period. Intestinal parasites are prevalent in the developing regions of the world. With increasing travel to and from endemic regions, changing immigration patterns, and the expansion of transplant medicine in developing countries, they are increasingly recognized as a source of morbidity and mortality in solid‐organ transplant recipients. Parasitic infections may be acquired from the donor allograft, from reactivation, or from de novo acquisition post‐transplantation. Gastrointestinal multiplex assays have been developed; some of the panels include testing for Cryptosporidium, Cyclospora, Entamoeba histolytica, and Giardia, and the performance is comparable to conventional methods. A polymerase chain reaction test, not yet widely available, has also been developed to detect Strongyloides in stool samples. New recommendations have been developed to minimize the risk of Strongyloides donor‐derived events. Deceased donors with epidemiological risk factors should be screened for Strongyloides and recipients treated if positive as soon as the results are available. New therapeutic agents and studies addressing the optimal treatment regimen for solid‐organ transplant recipients are unmet needs. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

128. A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.

Author

Mullane, Kathleen M, Winston, Drew J, Nooka, Ajay, Morris, Michele I, Stiff, Patrick, Dugan, Michael J, Holland, Henry, Gregg, Kevin, Adachi, Javier A, Pergam, Steven A, Alexander, Barbara D, Dubberke, Erik R, Broyde, Natalya, Gorbach, Sherwood L, and Sears, Pamela S

Subjects
ANTI-infective agents, DIAGNOSIS of diarrhea, AUTOGRAFTS, DIARRHEA, CLOSTRIDIUM diseases, DISEASES, DRUG side effects, HEMATOPOIETIC stem cell transplantation, HOMOGRAFTS, IMMUNOASSAY, MICROBIAL sensitivity tests, NEUTROPHILS, RANDOMIZED controlled trials, TREATMENT effectiveness, DISEASE incidence, BLIND experiment, ANTIBIOTIC prophylaxis, NUCLEIC acid amplification techniques, FIDAXOMICIN, DISEASE complications, ADULTS, DIAGNOSIS, PREVENTION
Abstract

Background Clostridium difficile –associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention of CDAD in HSCT patients. Methods In this double-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by transplant type (autologous/allogeneic) were randomized to once-daily oral fidaxomicin (200 mg) or a matching placebo. Dosing began within 2 days of starting conditioning or fluoroquinolone prophylaxis and continued until 7 days after neutrophil engraftment or completion of fluoroquinolone prophylaxis/clinically-indicated antimicrobials for up to 40 days. The primary endpoint was CDAD incidence through 30 days after study medication. The primary endpoint analysis counted confirmed CDAD, receipt of CDAD-effective medications (for any indication), and missing CDAD assessment (for any reason, including death) as failures; this composite analysis is referred to as "prophylaxis failure" to distinguish from the pre-specified sensitivity analysis, which counted only confirmed CDAD (by toxin immunoassay or nucleic acid amplification test) as failure. Results Of 611 subjects enrolled, 600 were treated and analyzed. Prophylaxis failure was similar in fidaxomicin and placebo recipients (28.6% vs 30.8%; difference 2.2% [-5.1, 9.5], P =.278). However, most failures were due to non-CDAD events. Confirmed CDAD was lower in fidaxomicin vs placebo recipients (4.3% vs 10.7%; difference 6.4% [2.2, 10.6], P =.0014). Drug-related adverse events occurred in 15.0% of fidaxomicin recipients and 20.0% of placebo recipients. Conclusions While no difference was demonstrated between arms in the primary analysis, results of the sensitivity analysis demonstrated that fidaxomicin significantly reduced the incidence of CDAD in HSCT recipients. Clinical Trials Registration NCT01691248 [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

130. Unique characteristics of cryptococcosis identified after death in patients with liver cirrhosis: comparison with concurrent cohort diagnosed antemortem

Author

Singh, Nina, primary, Sifri, Costi D, additional, Silveira, Fernanda P, additional, Miller, Rachel, additional, Gregg, Kevin S, additional, Huprikar, Shirish, additional, Lease, Erika D, additional, Zimmer, Andrea, additional, Dummer, J Stephen, additional, Spak, Cedric W, additional, Koval, Christine, additional, Banach, David B, additional, Shroff, Miloni, additional, Le, Jade, additional, Ostrander, Darin, additional, Avery, Robin, additional, Eid, Albert, additional, Razonable, Raymund R, additional, Montero, Jose, additional, Blumberg, Emily, additional, Alynbiawi, Ahlaam, additional, Morris, Michele I, additional, Randall, Henry B, additional, Alangaden, George, additional, Tessier, Jeffrey, additional, Cacciarelli, Thomas V., additional, Wagener, Marilyn M, additional, and Sun, Hsin Yun, additional

Published
2016
Full Text
View/download PDF

131. Impact of Viral Load on Eradication of Cytomegalovirus (CMV) Viremia Amongst High-risk Allogeneic Stem Cell Transplant (SCT) Recipients

Author

Camargo, Jose F., primary, Shimose, Luis, additional, Bueno, Maria X., additional, Rosa, Rossana, additional, Jeyakumar, Nikeshan, additional, Morris, Michele I, additional, Abbo, Lilian M., additional, Simkins, Jacques, additional, Alencar, Maritza C., additional, Benjamin, Cara, additional, Goodman, Mark, additional, Byrnes, John J., additional, Lekakis, Lazaros J., additional, Pereira, Denise, additional, and Komanduri, Krishna V., additional

Published
2016
Full Text
View/download PDF

134. A cluster of donor‐derived <italic>Cryptococcus neoformans</italic> infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature.

Author

Camargo, Jose F., Simkins, Jacques, Alcaide, Maria L., Anjan, Shweta, Morris, Michele I., Abbo, Lilian M., Schain, Denise C., Gonzalez, A. Adrian, Guerra, Giselle, Roth, David, Kupin, Warren L., Mattiazzi, Adela, Tan, Yaohong, and Milikowski, Clara

Subjects
CRYPTOCOCCUS, TRANSPLANTATION of organs, tissues, etc., DISEASES, KIDNEY diseases, BIOPSY
Abstract

Abstract: Donor‐derived infections (DDIs) are a very rare but potentially devastating complication of solid organ transplantation. Here we present a cluster of proven donor‐derived cryptococcal infection in the kidney, liver, and lung recipients from a single donor. Remarkably, the onset of illness in the kidney and liver recipients occurred more than 8‐12 weeks after transplantation, which is beyond the incubation period previously reported for donor‐derived cryptococcosis. DDI should always be considered in the differential diagnosis of transplant recipients admitted with febrile illness, even when presenting beyond the first month post‐transplant. Communication between reference laboratories, transplant centers, and organ procurement organizations is critical to improve outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

136. Cryptococcosis in Patients With Cirrhosis of the Liver and Posttransplant Outcomes

Author

Singh, Nina, primary, Sifri, Costi D., additional, Silveira, Fernanda P., additional, Miller, Rachel, additional, Gregg, Kevin S., additional, Huprikar, Shirish, additional, Lease, Erika D., additional, Zimmer, Andrea, additional, Dummer, J. Stephen, additional, Spak, Cedric W., additional, Koval, Christine, additional, Banach, David B., additional, Shroff, Miloni, additional, Le, Jade, additional, Ostrander, Darin, additional, Avery, Robin, additional, Eid, Albert, additional, Razonable, Raymund R., additional, Montero, Jose, additional, Blumberg, Emily, additional, Alynbiawi, Ahlaam, additional, Morris, Michele I., additional, Randall, Henry B., additional, Alangaden, George, additional, Tessier, Jeffrey, additional, Wagener, Marilyn M., additional, and Sun, Hsin Yun, additional

Published
2015
Full Text
View/download PDF

137. Donor-Derived Transmission Events in 2013

Author

Green, Michael, primary, Covington, Shandie, additional, Taranto, Sarah, additional, Wolfe, Cameron, additional, Bell, Walter, additional, Biggins, Scott W., additional, Conti, David, additional, DeStefano, G. David, additional, Dominguez, Edward, additional, Ennis, Donna, additional, Gross, Thomas, additional, Klassen-Fischer, Mary, additional, Kotton, Camille, additional, LaPointe-Rudow, Dianne, additional, Law, Yuk, additional, Ludrosky, Kristen, additional, Menegus, Marilyn, additional, Morris, Michele I., additional, Nalesnik, Michael A., additional, Pavlakis, Martha, additional, Pruett, Timothy, additional, Sifri, Costi, additional, and Kaul, Daniel, additional

Published
2015
Full Text
View/download PDF

138. 221 - Impact of Cytomegalovirus (CMV) Viral Load on Probability of Spontaneous Clearance and Efficacy of Pre-Emptive Therapy Among CMV Seropositive Allogeneic Stem Cell Transplant Recipients

Author

Camargo, Jose F., Shimose, Luis, Bueno, Maria X., Rosa, Rossana, Jeyakumar, Nikeshan, Morris, Michele I., Abbo, Lilian M., Simkins, Jacques, Alencar, Maritza C., Benjamin, Cara L., Wieder, Eric, Kimble, Erik L., Jimenez, Antonio M., Beitinjaneh, Amer, Goodman, Mark, Byrnes, John J., Lekakis, Lazaros, Pereira, Denise, and Komanduri, Krishna V.

Published
2017
Full Text
View/download PDF

140. Risk factors for mortality in patients with mucormycosis

Author

Spellberg, Brad, primary, Kontoyiannis, Dimitrios P., additional, Fredricks, David, additional, Morris, Michele I., additional, Perfect, John R., additional, Chin-Hong, Peter V., additional, Ibrahim, Ashraf S., additional, and Brass, Eric P., additional

Published
2012
Full Text
View/download PDF

141. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

Author

Bumbacea, Dragos, primary, Arend, Sandra M., additional, Eyuboglu, Fusun, additional, Fishman, Jay A., additional, Goletti, Delia, additional, Ison, Michael G., additional, Jones, Christine E., additional, Kampmann, Beate, additional, Kotton, Camille N., additional, Lange, Christoph, additional, Ljungman, Per, additional, Milburn, Heather, additional, Morris, Michele I., additional, Muller, Elmi, additional, Muñoz, Patricia, additional, Nellore, Anoma, additional, Rieder, Hans L., additional, Sester, Urban, additional, Theodoropoulos, Nicole, additional, Wagner, Dirk, additional, and Sester, Martina, additional

Published
2012
Full Text
View/download PDF

142. The Effect of Donor-Recipient Cytomegalovirus Serology on Adult Liver Transplantation: A Single Center Experience

Author

Tryphonopoulos, Panagiotis, primary, Weppler, Debbie, additional, Morris, Michele I., additional, Russo, Cristina, additional, Nishida, Seigo, additional, Levi, David M., additional, Moon, Jang, additional, Tekin, Akin, additional, Selvaggi, Gennaro, additional, Island, Eddie, additional, Arosemena, Leopoldo, additional, Ruiz, Phillip, additional, and Tzakis, Andreas G., additional

Published
2011
Full Text
View/download PDF

144. Cutaneous cryptococcosis in solid organ transplant recipients

Author

Sun, Hsin-Yun, primary, Alexander, Barbara D., additional, Lortholary, Olivier, additional, Dromer, Francoise, additional, Forrest, Graeme N., additional, Lyon, G. Marshall, additional, Somani, Jyoti, additional, Gupta, Krishan L., additional, Busto, Ramon Del, additional, Pruett, Timothy L., additional, Sifri, Costi D., additional, Limaye, Ajit P., additional, John, George T., additional, Klintmalm, Goran B., additional, Pursell, Kenneth, additional, Stosor, Valentina, additional, Morris, Michele I., additional, Dowdy, Lorraine A., additional, Muñoz, Patricia, additional, Kalil, Andre C., additional, Garcia-Diaz, Julia, additional, Orloff, Susan L., additional, House, Andrew A., additional, Houston, Sally H., additional, Wray, Dannah, additional, Huprikar, Shirish, additional, Johnson, Leonard B., additional, Humar, Atul, additional, Razonable, Raymund R., additional, Fisher, Robert A., additional, Husain, Shahid, additional, Wagener, Marilyn M., additional, and Singh, Nina, additional

Published
2010
Full Text
View/download PDF

145. Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant RecipientsWith Cryptococcosis

Author

Osawa, Ryosuke, primary, Alexander, Barbara D., additional, Lortholary, Olivier, additional, Dromer, Françoise, additional, Forrest, Graeme N., additional, Lyon, G Marshall, additional, Somani, Jyoti, additional, Gupta, Krishan L., additional, del Busto, Ramon, additional, Pruett, Timothy L., additional, Sifri, Costi D., additional, Limaye, Ajit P., additional, John, George T., additional, Klintmalm, Goran B., additional, Pursell, Kenneth, additional, Stosor, Valentina, additional, Morris, Michele I., additional, Dowdy, Lorraine A., additional, Muñoz, Patricia, additional, Kalil, Andre C., additional, Garcia-Diaz, Julia, additional, Orloff, Susan, additional, House, Andrew A., additional, Houston, Sally, additional, Wray, Dannah, additional, Huprikar, Shirish, additional, Johnson, Leonard B., additional, Humar, Atul, additional, Razonable, Raymund R., additional, Fisher, Robert A., additional, Husain, Shahid, additional, Wagener, Marilyn M., additional, and Singh, Nina, additional

Published
2010
Full Text
View/download PDF

146. Rhodococcus Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients1.

Author

Vergidis, Pascalis, Ariza-Heredia, Ella J., Nellore, Anoma, Kotton, Camille N., Kaul, Daniel R., Morris, Michele I., Kelesidis, Theodoros, Shah, Harshal, Seo Young Park, Nguyen, M. Hong, Razonable, Raymund R., and Park, Seo Young

Subjects
TRANSPLANTATION of organs, tissues, etc., HEMATOPOIETIC stem cell transplantation, RHODOCOCCUS, DIABETES, OPPORTUNISTIC infections, ANTIBIOTICS, CORYNEBACTERIACEAE, GRAM-positive bacteria, IMMUNOSUPPRESSIVE agents, RESEARCH funding, CASE-control method, IMMUNOCOMPROMISED patients, ODDS ratio, DISEASE complications
Abstract

We conducted a case-control study of 18 US transplant recipients with Rhodococcus infection and 36 matched controls. The predominant types of infection were pneumonia and bacteremia. Diabetes mellitus and recent opportunistic infection were independently associated with disease. Outcomes were generally favorable except for 1 relapse and 1 death. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

147. Unrecognized Pretransplant and Donor-Derived Cryptococcal Disease in Organ Transplant Recipients.

Author

Hsin-Yun Sun, Alexander, Barbara D., Lortholary, Olivier, Dromer, Francoise, Graeme N. Forrest, Lyon, G. Marshall, Somani, Jyoti, Gupta, Krishan L., del Busto, Ramon, Pruett, Timothy L., Sifri, Costi D., Limaye, Ajit P., John, George T., Klintmalm, Goran B., Pursell, Kenneth, Stosor, Valentina, Morris, Michele I., Dowdy, Lorraine A., Munoz, Patricia, and Kalil, Andre C.

Subjects
CRYPTOCOCCOSIS, LIVER transplantation, HEART transplantation, TRANSPLANTATION of organs, tissues, etc., ORGAN donors, HOMOGRAFTS, DISEASES
Abstract

Background. Cryptococcosis occurring ⩽30 days after transplantation is an unusual event, and its characteristics are not known. Methods. Patients included 175 solid-organ transplant (SOT) recipients with cryptococcosis in a multicenter cohort. Very early-onset and late-onset cryptococcosis were defined as disease occurring ⩽30 days or >30 days after transplantation, respectively. Results. Very early-onset disease developed in 9 (5%) of the 175 patients at a mean of 5.7 days after transplantation. Overall, 55.6% (5 of 9) of the patients with very early-onset disease versus 25.9% (43 of 166) of the patients with late-onset disease were liver transplant recipients (P = .05). Very early cases were more likely to present with disease at unusual locations, including transplanted allograft and surgical fossa/site infections (55.6% vs 7.2%; P < .001). Two very early cases with onset on day 1 after transplantation (in a liver transplant recipient with Cryptococcus isolated from the lung and a heart transplant recipient with fungemia) likely were the result of undetected pretransplant disease. An additional 5 cases involving the allograft or surgical sites were likely the result of donor-acquired infection. Conclusions. A subset of SOT recipients with cryptococcosis present very early after transplantation with disease that appears to occur preferentially in liver transplant recipients and involves unusual sites, such as the transplanted organ or the surgical site. These patients may have unrecognized pretransplant or donor-derived cryptococcosis. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

148. Hepatitis flare in hepatitis B core antibody positive kidney recipients treated with rituximab.

Author

Raja, Mohammed, Natori, Yoichiro, Donato-Santana, Christian, De Lima, Daniela, Centeno, Alexandra, Mattiazzi, Adela, and Morris, Michele I.

Subjects
HEPATITIS B, HEPATITIS, HEPATITIS associated antigen, CHRONIC hepatitis B
Abstract

We read with interest the recent retrospective study by Querido et al[1] investigating the incidence of Hepatitis B virus (HBV) reactivation in kidney transplant (KT) recipients with positive anti-Hepatitis B core (HBcAb) and negative Hepatitis B surface antigen (HBsAg). Only 6/55 patients (11%) were on HBV prophylaxis, with 5 patients receiving HBV active therapy as part of HIV antiretroviral therapy (ART), while one patient was on entecavir. [Extracted from the article]

Published
2020
Full Text
View/download PDF

149. Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients— Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Author

La Hoz, Ricardo M. and Morris, Michele I.

Subjects
*COMMUNICABLE diseases, *TRANSPLANTATION of organs, tissues, etc., *CHAGAS' disease, *PROTOZOAN diseases, *COMMUNITIES of practice, *EMERGING infectious diseases, *TRICHOMONIASIS
Abstract

These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of tissue and blood protozoal infections in the pre‐ and post‐transplant period. Significant new developments in the field have made it necessary to divide the previous single guideline published in 2013 into two sections, with the intestinal parasites separated from this guideline devoted to tissue and blood protozoa. The current update reflects the increased focus on donor screening and risk‐based recipient monitoring for parasitic infections. Increased donor testing has led to new recommendations for recipient management of Toxoplasma gondii and Trypanosoma cruzi. Molecular diagnostics have impacted the field, with access to rapid diagnostic testing for malaria and polymerase chain reaction testing for Leishmania. Changes in Babesia treatment regimens in the immunocompromised host are outlined. The risk of donor transmission of free‐living amebae infection is reviewed. Changing immigration patterns and the expansion of transplant medicine in developing countries has contributed to the recognition of parasitic infections as an important threat to transplant outcomes. Medications such as benznidazole and miltefosine are now available to US prescribers as access to treatment of tissue and blood protozoa is increasingly prioritized. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

150. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.

Author

Camargo, Jose F., Morris, Michele I., Anderson, Anthony D., Rosa, Rossana, Kimble, Erik, and Komanduri, Krishna V.

Subjects
*CYTOMEGALOVIRUSES, *CELL transplantation, *TRANSPLANTATION of organs, tissues, etc.
Abstract

Background: Cytomegalovirus (CMV) infection is the most common infection following hematopoietic cell transplantation (HCT). Preemptive antiviral therapy is highly effective at halting viral replication and preventing CMV disease; however, recurrence rates after clearance of CMV DNAemia are high (50‐70%). Current treatment guidelines recommend maintenance therapy after initial clearance. Yet, the effectiveness of this intervention to prevent recurrence is not well defined. Objectives: We aimed to assess the impact of maintenance therapy on the probability of recurrent CMV in allogeneic HCT recipients with early CMV reactivation. Study design: Sixty‐six patients with an initial episode of early CMV reactivation who achieved viral clearance in response to preemptive therapy were included. We compared the incidence of recurrent CMV DNAemia in patients who received maintenance therapy vs those who underwent early discontinuation of antiviral therapy. Results: Recurrence occurred in 47/64 (73%) patients, including 11/14 (79%) patients without maintenance therapy and 36/50 (72%) of patients who received maintenance therapy (P = 0.74). The propensity score adjusted risk ratio for the effect of maintenance therapy on recurrence was 0.89 (95% CI 0.64‐1.25; P = 0.41). In a time to event analysis using the unweighted cohort, the 90‐day probability of CMV recurrence was similar between patient groups independent of maintenance therapy administration (54% vs 64% for maintenance vs non‐maintenance groups, respectively; log‐rank P = 0.37). Conclusion: These data suggest that maintenance antiviral therapy does not reduce the incidence of CMV recurrence while off therapy and is of limited value in HCT recipients who have successfully eradicated CMV DNAemia in response to preemptive therapy. Larger studies in this area are needed. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results